In response to the core policy of the "Healthy China 2030" strategy of "shifting the focus forward and shifting the focus downwards", breaking down the barriers to scientific research and transformation in the fields of immune cell technology and HPV related disease prevention and treatment, and promoting cutting-edge medical technology from laboratories to the public's livelihood, on August 18, 2026, the strategic cooperation signing ceremony for the transformation of research results of Meinian Health Group, Meiyin Gene Joint Qianjing Biology, Anqin Kangyang NK, and HPV technology was held at Beidaihe Hospital.

Liu Chunmei, Deputy District Mayor of Beidaihe District, Ma Yanhua, Director of Beidaihe District Health Bureau, Song Changxing, President of Beidaihe Hospital and other government and public medical system leaders witnessed the scene; Xu Tao, President of Meinian Health Group, Lin Lin, Senior Vice President of Meinian Group, and Zhai Yong, Vice President of Meiyin Gene, as well as the core teams of Qianjing Biology and Anqin Health Care, and experts in HPV special projects, attended the event to embark on a new journey of multidimensional collaborative innovation in medical research, production, health care, and wellness.

This cooperation relies on the industrial and policy advantages of Beidaihe National Life and Health Industry Innovation Demonstration Zone, focusing on the transformation of scientific research achievements in NK cell immune technology and HPV therapeutic vaccine technology. All parties will integrate the entrance of national health screening, core technologies of genetic testing, biological research and development capabilities, public clinical quality control system, and comprehensive health care service scenarios, open up the full chain service loop of "physical examination screening gene testing technology application clinical quality control health care management", break through the pain points of difficult landing of cutting-edge medical technology and insufficient universality in the industry, and use the deep integration mode of medical research, production, health care, empower the precise health management of the people, and promote the high-quality development of the regional health industry.

Facing the pain points of people's livelihood and health, building a collaborative closed loop of medical research, production, health and wellness

The current national health demand continues to upgrade, and immunization health maintenance and precise prevention and control of HPV related diseases have become key public health and livelihood issues. HPV infection covers all age groups, and according to the national physical examination data of Meinian Health Group, the platform detected 804000 positive samples of HPV. The HPV infection rate among the general population in China remains high, while facing practical challenges such as insufficient vaccination rates, limited screening coverage, lack of specific treatment drugs, and weak accessibility of cutting-edge technologies. A large number of high-quality technologies have long been trapped in scientific research settings, making it difficult to benefit the general public.

NK cell immune technology is an important direction for tumor adjuvant therapy and immune health regulation. The 11 year long-term follow-up cohort of The Lancet confirms that NK cell killing activity is highly correlated with cancer risk; A large-scale study at Peking Union Medical College Hospital also confirmed that NK cells are a key defense line against immune aging in middle-aged and elderly populations. However, this technology has long been plagued by bottlenecks such as a disconnect between scientific research and livelihood scenarios, a lack of standardized implementation systems, and insufficient public awareness. Overall, cutting-edge biotechnology generally faces the industry dilemma of "emphasizing scientific research, neglecting transformation, and difficult to achieve universal benefits", and there is a clear gap between scientific research achievements and public health needs.

Liu Chunmei, Deputy District Mayor of Beidaihe District, stated that the landing of numerous leading enterprises in Beidaihe is a recognition of the local business environment for the life and health industry. As a national demonstration zone for innovation in the life and health industry, Beidaihe continues to improve policy support, build innovation platforms, adhere to a serious medical approach, and maintain rigor and prudence in project selection and enterprise cooperation. We hope that all parties to the contract can use this as a starting point to transform laboratory research achievements into health services that are perceptible, accessible, trustworthy, and usable for the general public, and explore new paths in the fields of tumor early screening, immune health, and HPV disease prevention and control. Relying on the massive customer base of Meinian and the coastal cultural, tourism, and health resources of Beidaihe, we aim to create an integrated service model of screening, treatment, and health regulation. The district committee and government will also continue to provide supporting support and welcome more innovative medical projects to be implemented.

This project is being carried out under the guidance and supervision of the Beidaihe District Committee, District Government, and District Health Bureau, strictly adhering to medical ethics and safety bottom line. Collaboration breaks away from the traditional model of single technology authorization and single point project cooperation, promoting the deep integration of prevention screening ports, cutting-edge biotechnology, public clinical quality control, and comprehensive health care scenarios, building a complete industry chain of "public health entrance directly to clinical technology landing, extending long-term health management", and implementing the concept of "prevention first, full process management" in Healthy China.

Xu Tao, President of Meinian Health Group, pointed out that this four party alliance is an important milestone in the field of biomedical new technology treatment. Meinian Health Group and Meiyin Gene have leading national capabilities in health screening, genetic testing, and big data research. Combined with the public platform of Beidaihe Hospital and the strength of Qianjing Biotechnology, the four parties have connected the chains of early screening detection, precise evaluation, cell therapy, and scientific research transformation, opening a new chapter in the standardized, industrialized, and academic development of Beidaihe's biomedical new technologies. The group's cell project team will form a special group to refine the implementation measures with Beidaihe Hospital and Qianjing Biotechnology, adhere to compliance in medical practice, prioritize safety, and ensure medical quality and public rights.

Song Changxing, the director of Beidaihe Hospital, introduced that the hospital is the only second-class comprehensive public hospital under the Beidaihe District Government, and relevant cases of cell therapy have been implemented. We look forward to the implementation of NK and HPV projects in our hospital, and also hope to expand our physical examination business, establish regional medical testing centers and other diversified cooperation in the future, attracting more high-quality medical projects to root in Beidaihe and serve local and out of town patients.

Collaborating parties leverage their differentiated advantages to achieve complementary capabilities

By the end of 2025, Meinian Health has established over 560 physical examination centers in more than 290 cities across the country, serving approximately 25 million customers and accumulating over 260 million national health data. It has completed high-risk population screening, hierarchical management, and targeted referral. Lin Lin, Senior Vice President of Meinian Group, stated that based on massive physical examination data, the proportion of sub healthy and mildly abnormal people is high, and there is a strong demand for prevention and adjustment. The plan is to create a 3-15 day customized service for Beidaihe travel and health care for the Beijing Tianjin customer group.

Meiyin Gene, a Hong Kong listed company, is deeply involved in the field of genetic testing. It has established mature technological barriers in the areas of tumor early screening, genetic typing, and health risk prediction, providing core technical foundations and professional testing support for projects. Meiyin Gene highly recognizes the urban brand, industrial supporting facilities, and policy environment of Beidaihe. ”According to Zhai Yong, Vice President of Meiyin Gene, the project will prioritize polishing the service system, consolidating real user experience, and expanding commercialization after completing model verification.

Qianjing Biotechnology exports multiple cutting-edge pipelines such as NK cells, mRNAHPV therapeutic vaccines, oncolytic viruses, CAR-T, etc. It has a nearly 20000 square meter GMP R&D and production base, and multiple pipelines have been clinically studied in top tier hospitals in China. Sun Jingxin, Chairman of Qianjing Biotechnology, stated that the project will gather expert teams from Peking University Cancer Hospital and West China Hospital to promote the project with rigorous clinical standards and strictly adhere to patient safety.

Beidaihe Hospital undertakes the implementation of eight major tumor cell adjuvant therapy projects, safeguarding clinical safety and ethical bottom lines; Anqin Health Care undertakes long-term follow-up after clinical intervention and Binhai Health Care Regulation, achieving the linkage of "clinical intervention+health care" business. The entire set of cooperation fills in the gaps of previous new technologies in terms of "heavy research and development, no landing, no follow-up, and no closed loop", forming a replicable technology and livelihood transformation system.

Strictly adhere to the safety bottom line when implementing technology, and create practical samples for the transformation of achievements

This cooperation clarifies two major directions for implementation: firstly, to establish a compliant referral service system, relying on the National Screening Network of Meinian, to orderly refer high-risk tumor and HPV positive populations to Beidaihe Hospital, and implement a special program for tumor cell assisted therapy; The second is to deepen the collaborative innovation between medical research enterprises, jointly build a highland for biomedical new technology research, carry out clinical trials and academic seminars, and accumulate local real-world clinical data. The entire project process strictly adheres to industry standards and medical ethics, prioritizes medical safety, and does not pursue rapid commercial expansion.

Ma Yanhua, Director of the Health Bureau of Beidaihe District, emphasized the full support for the four parties to carry out clinical research and technological exploration; Safety must be given top priority throughout the entire process, and responsibilities must be consolidated in all aspects of product storage and transportation, patient screening, and clinical treatment; Welcome enterprises and experts to continue exchanging ideas in Beidaihe. The project will be led by the Cell Project Team of Meinian Health Group as a special docking group, and Qianjing Biotechnology will gather top domestic experts to participate in clinical implementation. The Health Bureau will supervise the safety responsibility of the entire chain.

After the signing of the contract, a technical thematic sharing will be conducted. Zhou Yuan, Vice President of Qianjing Biotechnology, introduced that the release index of NK cells is higher than the national standard. Under the condition of a 1:1 ratio of efficacy to target in vitro experiments, the 6-hour killing rate can reach 83%, which is expected to reduce circulating tumor cells and reduce the risk of distant metastasis after surgery.

Han Liang, an expert in the therapeutic HPV project, mentioned that there is currently no specific treatment drug for HPV virus in China. The mRNA therapeutic HPV vaccine focuses on high-risk types 16 and 18. Phase I clinical data shows that the HPV virus conversion rate is greater than 95%, and the complete regression rate of precancerous lesions is 66.7%. It can preserve the reproductive function of women of childbearing age. Currently, multi center clinical trials have been carried out at Peking University People's Hospital and the Cancer Hospital of the Chinese Academy of Sciences.

Liu Guanghua, deputy general manager of Meinian Group, said that Meinian had transformed into a digital active health service platform, and a large number of tumors HPV、 Abnormal blood glucose samples, relying on the AI comprehensive examination system to achieve an accuracy rate of 99.8%, practicing the full cycle health management of "3 hours of physical examination, 365 days of service". On the one hand, it completes targeted referral for high-risk populations, and on the other hand, it collaborates with universities and medical institutions to conduct queue research, providing a population data base for technological iteration.

This strategic cooperation is an important practice of collaborative innovation in the integration of medical research, production, health and wellness. Connect the complete chain of "scientific research innovation clinical verification national screening landing service long-term management" in the industrial sector, provide replicable samples for the compliance transformation of domestic biomedical technology, and help upgrade the Beidaihe National Life and Health Industry Innovation Demonstration Zone. The livelihood sector focuses on the two high-risk health risks of tumor immunity and HPV infection, promotes clinical translation under the framework of public healthcare, promotes the transformation of scientific research achievements into universal health services, and implements early screening, diagnosis, and intervention of diseases.

In the future, all parties will continue to deepen collaboration, steadily promote technological iteration, clinical trials, and health education, polish the full cycle health service system, empower national health management throughout the entire life cycle with technological innovation, and help the implementation of the "Healthy China 2030" strategy, injecting new momentum into the high-quality development of the big health industry.

Reminder: The NK cell and mRNA therapeutic HPV vaccine related technologies mentioned in the article are still in the stage of clinical research and achievement transformation. The data in the article is from clinical research and does not constitute any diagnosis or treatment recommendations.